223 results about "Pharmaceutical industry" patented technology

The invention provides a specific sequence nucleic acid molecule and application thereof as a PDRN, and relates to the technical field of biology. A novel nucleic acid molecule with a specific sequence is obtained, and the sequence has certainty, biological activity and stable product quality. The PDRN of the specific sequence does not have cytotoxicity, is high in safety and has a wide application prospect. Moreover, compared with the extracted PDRN, the PDRN with a specific sequence is found for the first time, the product has a remarkable effect of promoting VEGF expression, cell damage can be effectively repaired, and a novel skin-care and repairing functional component is provided for the industries of cosmetics and medicines. The invention further provides a preparation method of the PDRN with the specific sequence, and the preparation method is simple and suitable for popularization, application and industrial production.

The invention provides a method for detecting the content of liquiritin and glycyrrhizic acid in liquorice decoction pieces based on hyperspectrum, and relates to a method for rapidly and nondestructively predicting the content of index components of the liquorice decoction pieces by using a hyperspectrum technology. The method comprises the following implementation steps: acquiring a hyperspectral image of the liquorice decoction piece, determining the liquid phase content of the liquorice decoction piece, preprocessing the hyperspectral image, establishing a content prediction model, and quickly and nondestructively detecting the liquorice decoction piece. The method comprises the following steps: collecting licorice decoction pieces in a short-wave infrared band by using a hyperspectral imaging technology, determining the contents of liquiritin and glycyrrhizic acid in a collected sample through liquid chromatography, extracting characteristic wavelengths according to the content measurement data, comparing the advantages and disadvantages of different characteristic variable extraction methods and content prediction models, and determining the content of glycyrrhizic acid in the licorice decoction pieces. Therefore, rapid nondestructive detection of the liquiritin and glycyrrhizic acid content in the licorice decoction pieces is realized, an analysis method is provided for rapid grading and screening of the traditional Chinese medicine decoction pieces, digitization, intelligence and greenization of the traditional Chinese medicine industry are promoted, and improvement of the equipment manufacturing level of the pharmaceutical industry is promoted.

The invention discloses a pollution source dynamic acquisition and monitoring method and system, relates to the technical field of pollution source dynamic acquisition and monitoring, and solves the problem that a scheme capable of sensing the pollution situation and autonomously optimizing the monitoring frequency is difficult to set in pharmaceutical production. And a dynamic threshold is difficult to set according to the dynamic influence of the environmental variable on the pollution diffusion rule. According to the method, the predicted pollution concentration of the current time period is obtained through the pre-evaluation model; determining the data acquisition frequency of the current time period according to the pollution concentration of the previous time period and the predicted pollution concentration of the current time period; acquiring the pollution concentration of each pollution source in the current time period based on the data acquisition frequency of the current time period; determining an alarm instruction of each pollution source based on the pollution concentration in the current time period, and giving an alarm based on the alarm instruction; according to the invention, environmental risk control can be changed from passive response to active prevention, and technical support is provided for green production and sustainable development of the pharmaceutical industry.

The invention belongs to the technical field of plant tissue culture, and particularly relates to an induction method of adventitious roots of cinnamomum camphora. According to the method disclosed by the invention, the adventitious root induction rate of the adventitious root of the cinnamomum camphora is remarkably improved by establishing a sterile system of the cinnamomum camphora, culturing cluster buds and sterile seedlings, promoting rooting of tissue culture seedlings, inhibiting browning, enabling the adventitious buds to extend and inducing the adventitious root through three ways, so that the problems of shortage of borneol resources and high market demand are solved; the method for inducing the adventitious roots of the cinnamomum camphora can be used for industrial production, and sufficient raw materials are provided for extraction of borneol; according to the method, large-scale culture of the adventitious roots of the cinnamomum camphora is achieved, a large number of pharmaceutical raw materials can be obtained at low cost in a short time, and an integrated production system can be formed with the pharmaceutical industry. The technology has important practical significance for promoting the development of the cinnamomum camphora industry, expanding the application of the pharmaceutical field, constructing a rare and endangered traditional Chinese medicinal material breeding technology system and realizing sustainable development and utilization.

This invention discloses a highly efficient asymmetric synthesis method for aryl propionic acid drug molecules. The method uses racemic aldehydes as substrates and thiamine pyrophosphate-dependent enzymes as biocatalysts. Electrolysis is performed in a diaphragm-free electrolytic cell under conditions of an external redox dielectric and constant current, in a buffer salt solution and nitrogen atmosphere. This method achieves dynamic kinetic oxidation of aldehydes via bioelectrocatalysis, enabling the high-efficiency and high enantioselectivity synthesis of aryl propionic acid drug molecules. The method eliminates the need for redox agents and additives, is simple to operate, operates under mild reaction conditions, and is green and sustainable. This invention applies bioelectrocatalysis to asymmetric synthesis, providing a green and efficient new enzymatic synthetic route for the asymmetric synthesis of aryl propionic acid drug molecules, which has significant application prospects in the pharmaceutical industry.

The utility model discloses an anti-blocking filling machine for capsule medicine preparation and belongs to the technical field of medicine production. A medicine inlet is formed in the upper end of the shell, a stirring mechanism is arranged in the shell and fixedly connected with an anti-blocking mechanism, the anti-blocking mechanism is arranged in a conveying pipe, the conveying pipe is fixedly communicated with the upper end of the shell, a discharging port is formed in the lower end of the conveying pipe, an electronic valve is arranged on the discharging port, and the outer wall of the lower end of the conveying pipe is fixedly connected with a connecting frame. The connecting frame is fixedly connected with the fixing plate, the fixing plate is provided with a filling mechanism, and the filling mechanism corresponds to the discharging port. By means of the unique design and working principle, the capsule medicine preparation device has the remarkable advantages of being efficient in stirring, excellent in anti-blocking performance, accurate in filling, easy and convenient to operate, wide in application and the like, and efficient, reliable and automatic capsule medicine preparation equipment is provided for the pharmaceutical industry.

This invention provides specific sequence nucleic acid molecules and their applications as PDRNs, relating to the field of biotechnology. This invention yields novel specific sequence nucleic acid molecules with deterministic sequences, stable biological activity, and stable product quality. The PDRNs with these specific sequences are non-cytotoxic, exhibit high safety, and have broad application prospects. Furthermore, this invention is the first to discover that specific sequence PDRNs, compared to extracted PDRNs, significantly promote VEGF expression and effectively repair cell damage, providing a novel skincare and repair ingredient for the cosmetics and pharmaceutical industries. This invention also provides a simple method for preparing specific sequence PDRNs, suitable for widespread application and industrial production.

The utility model provides a western medicine double -layer tablet production is with double hopper precision filling structure, belongs to production technical field, including first workstation, the surface of first workstation is installed with filling structure, and filling structure is used for filling to double -layer tablet, filling structure includes hopper, hopper fixedly arranged in the surface of first workstation, hopper sets up two, two hoppers are provided with the discharge gate, through the setting of filling structure, the transmission design of servo motor plus different number of teeth driven gear, through the transmission ratio of adjusting gear and pulley, can control the rotating speed of two hoppers inner impeller respectively, combine the accurate calculation of volume of impeller upper feed inlet, can realize independent, accurate quantitative feeding according to the filling amount demand (such as the upper layer and lower layer weight ratio of double -layer tablet) of two raw materials, makes two layers raw material weight deviation control in very small range, accords with the strict standard of tablet weight difference of pharmaceutical industry, ensures the medicine dose accurate.

This invention belongs to the field of pharmaceutical drying technology and discloses a pharmaceutical drying and automatic lifting mixing device based on negative pressure fluidization, including a machine body, a lifting cylinder, and a second waste gas guide channel. In use, the invention drives the spiral lifting blades through a waste gas power transmission component, achieving automatic lifting and discharge of the dried material. This eliminates the need for manual transfer, reducing operator workload, improving production efficiency, and avoiding material contamination during transfer, thus meeting the clean production requirements of the pharmaceutical industry. Simultaneously, the pneumatic reciprocating lifting component drives the periodic lifting and lowering of the material plate, continuously agitating the material during the drying process. This breaks the limitations of static drying in existing equipment, ensuring that the material is uniformly exposed to hot air from all directions. This avoids problems such as uneven heating, clumping, and incomplete drying caused by material accumulation, guaranteeing the drying quality of pharmaceutical materials and preventing the destruction of active ingredients.

This utility model relates to a cleanroom air conditioning and dust removal system, belonging to the field of cleanroom technology in the pharmaceutical industry. The system includes a combined cleanroom air conditioning unit, a bag filter, an air supply duct network, a high-efficiency filter air outlet, a return air duct network, a dust removal exhaust hood, a dust removal static pressure box, a dust concentration sensor, and a controller. The bag filter is rigidly connected to the air conditioning unit side-by-side and fixed to the floor of the equipment room, eliminating interference from the equipment to the cleanroom. The outlet of the bag filter is directly connected to the mixing section of the air conditioning unit through the return air duct network, forcibly reusing the dust-removed air as return air. The dust concentration sensor is embedded in the inner wall of the dust removal static pressure box, directly exposed to the dust-laden airflow channel. This application significantly reduces the air conditioning cooling and heating load by physically reducing the demand for fresh air; the centralized layout of the equipment room frees up space in the cleanroom, improving the convenience of operation and maintenance; and the closed-loop dust collection and multi-stage filtration ensure the stability of cleanliness levels D and above.

This application discloses a method and device for aligning pharmaceutical entity data based on multimodal feature fusion. The method includes: acquiring multi-source data records containing entity name, first identity identifier, second identity identifier, related person information, and address information; constructing a core identity feature tuple composed of the entity name and dual identity identifiers to perform a first-level analysis; when the first-level analysis result is a partial mismatch, performing a second-level analysis based on the consistency of related person information and semantic proximity of addresses to determine whether the records point to the same entity; and merging and updating data determined to be from the same entity based on the date of the valid certificate. This application effectively addresses the unique "separation of licenses and permits" and information inconsistency issues in the pharmaceutical industry, significantly improving the accuracy and automation level of entity data alignment.

The group of inventions relates to the field of medicine, pharmacology and the chemical and pharmaceutical industry and includes an improved method for producing (10S, 13S, 16R, 17R)-17-hydroxy-10,13,16-trimethyl-17-propanoyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthrene-3-one (compound of formula (I)) and the use thereof for industrial batch, semi-continuous and continuous chemical production. Also described is a method for producing an intermediate compound, Vamorolone Acetate. The method for producing the compound of formula (I) is carried out according to the schema depicted. The production method makes it possible to produce the compound of formula (I) with a purity suitable for the use thereof in a finished dosage form for subjects requiring treatment for Duchenne muscular dystrophy. Thus, the technical results of the present invention consist in an improved production method which results in: a high yield and chemical purity, including stereoisomeric purity, of the compound of formula (I) and intermediate products in the synthesis of the compound of formula (I), which are suitable for use in a finished dosage form for subjects requiring treatment for Duchenne muscular dystrophy; the adaptability of the synthesis of the compound of formula (I) to industrial production; environmentally-friendly production; and a decrease in the formation of undesirable by-products.

Cleaning-in-place (CIP) systems utilize membrane filters for purifying liquid substances in many industries, including but not limited to, the dairy industry, breweries, pharmaceutical industry, and the food industry. These membrane filters undergo a rigorous cleaning process that despite cleaning can leave foulants on the membranes which hamper filter effectiveness. In addition to the cleaning, enzymes can be applied to the membranes to remove foulants and restore filtering effectiveness. However, introduction of enzymes into these CIP systems can be problematic if enzymes remain after cleaning. This disclosure provides a system and methods to mimic the membrane modules and verify that a correct inactivation procedure occurred. The systems and methods include a separate membrane sample so that no membrane modules need be removed to verify full enzyme inactivation.

The utility model relates to low temperature crystallization technical field, and disclose a kind of low temperature crystallization device of convenient energy saving, including base, the top end of base is fixedly connected with base at left side place close, the middle part of base is fixedly sleeved with double-layer heat preservation crystallization jar, the top end of double-layer heat preservation crystallization jar is fixedly connected with protective shell, the top end middle part of base is fixedly connected with support seat, the top end right side of base is fixedly connected with mixing tank, the rear side of double-layer heat preservation crystallization jar is equipped with refrigerant outlet, and then backflow to refrigeration compressor through refrigerant outlet, pass through the flow of multiple-point temperature sensor data adjustment, the accurate cooling crystallization of mixed solution in double-layer heat preservation crystallization jar, open electric valve two, high temperature refrigerant is transferred to the heat preservation layer of mixing tank through high temperature refrigerant pipe, heat exchange is carried out to the medical intermediate mixed solution to be preheated, make medical intermediate mixed solution temperature rise, simultaneously make high temperature refrigerant cool, it is favorable to improve energy utilization, guarantee the development demand of energy saving and cost reduction of pharmaceutical industry.

The application discloses a kind of methyl aspartate lyase EcMAL mutant and its preparation method and application, belong to enzyme engineering technical field.The methyl aspartate lyase EcMAL mutant is any one of mutant EcMAL-M1, mutant EcMAL-M2, mutant EcMAL-M3 and mutant EcMAL-M4.The application is obtained methyl aspartate lyase EcMAL mutant by the mutation of the 329th, 331st, 361st and 365th amino acid sites of methyl aspartate lyase combined with high-throughput screening method.The mutant changes the previous recombinant enzyme only L-aspartic acid production status, so that it is possible to produce D-aspartic acid with methyl aspartate lyase as biological catalyst, and it is expected to be used in pharmaceutical industry.

The utility model provides a system for processing high hardness concentrated salt water of pharmaceutical industry, including front end processing unit, electrochemistry removes hard unit, tubular membrane equipment, weak acid resin removes hard unit and evaporimeter. Front end processing unit is used to pretreatment to pharmaceutical wastewater, electrochemistry removes hard unit with front end processing unit connection, and electrochemistry removes hard unit produces flocculating agent for gathering suspended particles through electrode, tubular membrane equipment is used to filter to the pharmaceutical wastewater after electrochemistry removes hard unit processing, weak acid resin removes hard unit is used to remove calcium magnesium ion to the pharmaceutical wastewater after tubular membrane equipment filtration, evaporimeter is used to evaporate to the concentrated water of weak acid resin removes hard unit export. The utility model provides a system for processing high hardness concentrated salt water of pharmaceutical industry, aims at can solve the problem that evaporimeter heat exchange pipe is scaled seriously in the process of treating pharmaceutical wastewater in prior art and leads to evaporimeter life reduction.

1. The name of the design product: photoelectric liquid level sensor (RLG1224Q1A). 2. The use of the design product: the design product is mainly used in the production, storage and transportation process of various liquid tanks and tanks in chemical industry, petrochemical industry, chemical fiber industry, chemical fertilizer industry, food industry, pharmaceutical industry, transportation industry and military industry. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

The invention relates to genetic and protein engineering and can be used in medicine and the pharmaceutical industry. Recombinant plasmid DNA pET23b-CBD-HS-ES-GLP1, pET-parB-CBD-HS-ES-GLP1 and pET23bKanR-CBD-HS-ES-GLP1 were constructed to provide the synthesis of a hybrid protein containing the GLP-1 polypeptide sequence in Escherichia coli cells. By transforming the E. coli BL21 (DE3) strain with plasmids pET23b-CBD-HS-ES-GLP1, pET-parB-CBD-HS-ES-GLP1 and pET23bKanR-CBD-HS-ES-GLP1, the CBD-HS-ES-GLP1 hybrid protein has been produced. A method of producing polypeptide GLP-1 has been developed, which involves preparing and cultivating a producer of a hybrid protein containing polypeptide GLP-1, followed by isolation and cleavage of the said hybrid protein. The invention enables the production of polypeptide GLP-1 with high yield and simplified technology.

The invention relates to the technical field of endoscope protective sleeve production, and discloses endoscope protective sleeve production equipment with a broken material detection function, which comprises a rack, a feeding module is arranged at the front end of the rack, a sleeve forming processing module is arranged at the rear end of the rack, and a conveying system for conveying a film is assembled on the rack. The feeding module comprises two feeding rollers which are distributed up and down, the design that the double-station up-down layout is combined with the material waiting station deflection is adopted, the double feeding rollers can achieve alternate feeding, the material waiting station is located below the equipment, the feeding rollers can deflect towards the outer side of the rack during material waiting, an operator can complete replacement of a large-weight film roll in an open area, and the replacement efficiency is improved. Meanwhile, the deflected material supplementing area is completely isolated from a production operation area, the risk that the deflected material supplementing area makes contact with a high-speed running component in the operation process is avoided, and the dual requirements of the pharmaceutical industry for operation convenience and safety are synchronously met.

Cleaning-in-place (CIP) systems utilize membrane filters for purifying liquid substances in many industries, including but not limited to, the dairy industry, breweries, pharmaceutical industry, and the food industry. These membrane filters undergo a rigorous cleaning process that despite cleaning can leave foulants on the membranes which hamper filter effectiveness. In addition to the cleaning, enzymes can be applied to the membranes to remove foulants and restore filtering effectiveness. However, introduction of enzymes into these CIP systems can be problematic if enzymes remain after cleaning. This disclosure provides a system and methods to mimic the membrane modules and verify that a correct inactivation procedure occurred. The systems and methods include a separate membrane sample so that no membrane modules need be removed to verify full enzyme inactivation.

The invention discloses a drug curative effect evaluation method and system using industrial big data, and relates to the technical field of pharmaceutical industry data analysis, and the method comprises the following steps: obtaining equipment process data and equipment residual data of a target object; performing double-clock fault-tolerant synchronous processing on the equipment process data to generate synchronous time sequence data, and performing quality evaluation on the synchronous time sequence data; and performing process slicing on the synchronous time sequence data, generating a process feature vector based on self-supervised window coding, and performing weight mapping and adjacency transmission processing on the process feature vector to generate a cumulative contribution matrix. According to the scheme, a linkage mechanism of the sensitivity table and the transfer coefficient is established, so that the process contribution matrix can reflect the dynamic change of the residual effect in real time, the dynamic transfer rule of equipment residues among different processes can be accurately captured, and meanwhile, the interference of low-quality data on the calculation process is eliminated through confidence correction.

The invention provides a process for preparing high-purity p-fluorobenzoyl chloride by a continuous falling film melt crystallization method, and belongs to the field of fine chemical purification, the process comprises the following steps: carrying out reduced pressure distillation on a reaction solution obtained by hydrolysis reaction of p-fluorobenzyl trichloride to obtain a p-fluorobenzoyl chloride crude product; the method comprises the following steps: carrying out dehydration treatment, carrying out falling film crystallization treatment, carrying out multi-stage programmed heating sweating treatment on precipitated crystals, removing an impurity enrichment liquid, collecting a high-purity p-fluorobenzoyl chloride melt, and finally obtaining an electronic-grade or pharmaceutical-grade product with chromatographic purity of more than or equal to 99.9%, and carrying out the whole process under inert gas protection. The continuous falling film melt crystallization method provided by the invention effectively solves the technical problem that p-fluorobenzoyl chloride is easy to hydrolyze and eutectic in the purification process, has the advantages of low energy consumption, environment-friendly process and high product purity, can remarkably improve the production efficiency and quality of p-fluorobenzoyl chloride, and is suitable for industrial production. The harsh requirements of electronics and medicine industries on high-purity raw materials are met.

The invention discloses a blister tray feeding and discharging device and a packaging production line, and relates to the technical field of feeding device tray feeding and discharging. The bubble cap feeding and discharging mechanism is used for supplying the bubble caps to the bubble cap transferring mechanism and recycling the bubble cap trays. Through automatic lifting of the object carrier, automatic clamping and pushing of the limiting clamping plate and automatic transferring of the second-stage conveying frame, ordered circulation of tray feeding, bubble cap transferring and tray recycling is achieved, full-process semi-automation of bubble cap supplying and tray recycling is achieved, frequent manual intervention is not needed, and the production efficiency is improved. Operators only need to be responsible for material supplement, equipment inspection and finished product collection, and do not need to participate in high-strength and repeated manual transfer, putting and other operations, so that the production efficiency is greatly improved, the labor intensity is greatly reduced, meanwhile, direct contact between workers and materials is reduced, the drug pollution risk is reduced, the production operation environment is improved, and the production cost is reduced. The clean production requirement of the pharmaceutical industry is met.

The invention discloses a knob type adjustable ceramic metering pump, and belongs to the technical field of metering pumps. The metering pump comprises a plurality of components such as a screw, a pump head cover, a sleeve cover, a sleeve, a column rod, an adjusting knob, a check ring and a bearing seat. The adjusting knob is rotated to extrude the copper pad, so that the angle of the check ring is changed to adjust the liquid amount, a special tool is not needed, and the adjustment is convenient; through bottom contact type positioning of the pump rod, the lower plane of the column rod is in light contact with the sleeve cover, the position of the column rod can be adjusted by rotating the bearing seat, dead volume is avoided, and the liquid injection precision is guaranteed. The problems that an existing micro ceramic pump is tedious in adjustment and insufficient in precision are solved, and the micro ceramic pump is suitable for high-precision liquid injection scenes of multiple industrial departments such as chemical engineering and pharmacy.

The invention relates to a crystal and application of a virus protease inhibitor, in particular to a crystal form of a compound 1 or pharmaceutically acceptable salt thereof and application thereof. The invention also relates to a preparation method of the crystal form, a composition containing the crystal and a pharmaceutical composition. The crystal form is stable, high in yield, mild in crystallization condition, suitable for industrial production and capable of well meeting the requirements of the pharmaceutical industry.

This invention belongs to the field of intelligent training technology in the pharmaceutical industry, and provides a non-contact virtual-real interactive simulation system and method for GMP drug production. It includes: a login authentication module for authenticating trainees' identities based on the virtual-real interactive simulation platform; after successful authentication, trainees can select a training mode; a startup module for activating a motion capture module and a real-time evaluation module after the virtual-real interactive simulation platform detects the selected training mode; a recognition module for capturing and recognizing trainees' actions in real time based on the motion capture module, and synchronizing with the virtual scene of a high-fidelity drug production line model in the training mode to obtain virtual environment feedback; a compliance judgment module for determining whether the trainee's operational compliance based on the virtual environment feedback exceeds a preset compliance level based on the real-time evaluation module; and a report generation module for recording training data under virtual environment feedback and generating an evaluation report stored in a database. This improves training efficiency.

This invention relates to the field of talent training quality assessment technology in medical and pharmaceutical colleges, and discloses a big data closed-loop assessment system for talent training quality in medical and pharmaceutical colleges. The system includes: a data acquisition module to collect multi-source training data; a preprocessing and fusion module to construct a talent training quality dataset; a big data closed-loop assessment module containing three-level indicator construction, multi-dimensional assessment, and result analysis units to complete the assessment and generate personalized reports; an intelligent feedback module to push and visualize the assessment results; a training optimization module to adapt rigid constraints and transform them into optimization measures; and a system iteration module to ensure the assessment system is updated synchronously with the pharmaceutical industry. This invention constructs a full-link closed loop, solving problems such as assessment disconnect and low accuracy, improving the quality of talent training and its industry adaptability, and adapting to the characteristics of medical and pharmaceutical college training.

The utility model discloses a more sanitary fast disassembly conveyor which comprises a round pipe frame, a driving roller assembly is arranged at the front end of the top of the round pipe frame, a driven roller assembly is rotationally arranged at the rear end of the top of the round pipe frame, the driving roller assembly and the driven roller assembly are connected through a belt, and a plurality of tug assemblies are arranged below the belt. A plurality of turning-up lock assemblies are arranged on the inner side of the belt, a free scraper assembly is arranged on the outer side of the front end of the belt, the whole design of the conveyor eliminates sanitation dead angles, the smooth surface, the seamless structure, the drainage design and the like of the conveyor are beneficial to keeping clean, the high sanitation requirements of the industries of food, medicine and the like are met, and the conveying efficiency is improved. And the product quality problem caused by pollution is effectively prevented.

The invention belongs to the technical field of food processing and biological medicines, and relates to a ginsenoside Rb1-lactoferrin composite emulsion with an anti-inflammatory effect and a preparation method thereof. The emulsion is prepared from the following components in parts by weight: 0.1 part of ginsenoside Rb1-lactoferrin complex, 7.5 to 8.5 parts of peanut oil and 1.4 to 2.4 parts of water. The emulsion disclosed by the invention has better stability, bioaccessibility and anti-inflammatory activity, does not have unstable phenomena such as layering and the like after being stored at room temperature for 35 days, and has a wide application prospect in food and pharmaceutical industries.

The utility model belongs to the technical field of pharmaceutical mixing, and particularly relates to a pharmaceutical mixing batch feeder which comprises supporting legs and a mixing cylinder arranged at the tops of the supporting legs, a telescopic assembly is arranged at the top of the mixing cylinder, a pneumatic pushing mixing assembly is arranged on the telescopic assembly, and the pneumatic pushing mixing assembly comprises a support arranged at the telescopic end of the telescopic assembly. A movable ring is installed at the bottom of the support, a sealing cavity is formed in the movable ring, a first elastic assembly is arranged on the inner wall of the bottom of the sealing cavity, a movable sealing ring is arranged on the first elastic assembly, and a first L-shaped guide pipe and a second L-shaped guide pipe which communicate with the sealing cavity are arranged at the bottom of the movable ring. According to the device, through a unique pneumatic pushing structure, the pushing mixing plate can perform bidirectional alternate movement, compared with a traditional single-direction stirring or mixing mode, pharmaceutical raw materials can be turned over more comprehensively, mixing dead angles are reduced, the pharmaceutical raw materials with different components are mixed more uniformly, and the quality stability of drugs is improved.